- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02779153
Acthar SLE (Systemic Lupus Erythematosus) (Acthar SLE)
Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to provide informed consent.
- Diagnosis of SLE according to the American College of Rheumatology revised criteria (fulfilled ≥ 4 criteria).
- Hematologic BILAG scores due to hemolytic anemia or thrombocytopenia of BILAG A (including hemolytic anemia with hemoglobin < 8.0 g/dL or platelet count < 25 x 109 l) or BILAG B (including hemolytic anemia with hemoglobin 8.0 - 9.9 g/dDL or platelet count 25 - 49 x 109 l) based on screening laboratory assessment.
- Currently taking prednisone ≥ 7.5 mg or equivalent for hematologic SLE for at least 2 weeks prior to screening.
- Use of antimalarials and NSAIDs (stable regimen within the 4 weeks prior to screening), as well as methotrexate, azathioprine, and mycophenolate mofetil (stable regimen within the 4 weeks prior to screening) are permitted but not required. If used, the regimen must remain stable through the study. An increase or addition of SLE medication at any time during the study is not permitted.
- Ability to comply with study procedures, which include SC injections of study medication, adhering to concomitant medication restrictions, and attending scheduled office visits.
Exclusion Criteria:
- Patients with a recent history (< 2 week prior to screening) of starting prednisone or equivalent.
- Patients with active nephritis, defined as serum creatinine > 2.5 mg/dL or protein/creatinine ratio (PCR) > 1.5 g/g, or patients that required hemodialysis within 3 months prior to screening.
- Active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis, or CNS vasculitis), requiring therapeutic intervention within 3 months prior to screening.
- Type 1 or type 2 diabetes mellitus (history of gestational diabetes is not an exclusion), or patients currently taking hypoglycemic medication.
Patients with a history of concomitant medication use as follows:
a. Receipt of the following within 1 month prior to screening: i. Any steroid injection (IM, intraarticular, or IV) b. Receipt of any of the following within 3 months prior to screening: i. Cyclosporine ii. Any non-biologic investigational drug c. Receipt of the following within 4 months prior to screening: i. IVIg ii. Plasmapheresis d. Receipt of cyclophosphamide within 6 months prior to screening e. Receipt of the following within 12 months prior to screening: i. B cell targeted therapy (rituximab or other anti-CD20 agent, anti-CD22 [epratuzumab], anti-CD52 [alentuzumab], or belimumab) ii. Abatacept iii. Any biologic investigational agent
Contraindication per Acthar Prescribing Information: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, or adrenal cortical hyperfunction.
- For the purposes of this study, osteoporosis is defined as evidence of vertebral or long bone fracture, or lumbar spine T-score > 2.0 standard deviations below the mean of the reference population.
- For the purposes of this study, history of peptic ulcer is defined as ≤ 6 months prior to screening.
- For the purposes of this study, congestive heart failure is defined as New York Heart Association Functional Class III-IV.
- For the purposes of this study, uncontrolled hypertension is defined as a mean systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg on ≥ 3 seated readings taken at least 5 minutes apart during the screening period.
Reproductive status:
- Women who are pregnant,
- Women who are breastfeeding,
- Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period, as evaluated by the Investigator (women of non-childbearing potential are those that have a history of hysterectomy, bilateral oophorectomy, or are postmenopausal with no history of menstrual flow for ≥ 12 months prior to screening).
- Immune System: Known immunocompromised status (not related to SLE or therapies for SLE), including individuals who have undergone organ transplantation or who are known to be positive for the human immunodeficiency virus.
- Patients with acute or chronic hepatitis C, or active hepatitis B infection, positive interferon gamma release assay (IGRA) or signs or symptoms concerning for active tuberculosis (TB); or use of antibiotics (antibacterial, antiviral, antifungal, or antiparasitic agent) within 4 weeks of randomization for treatment of an active infection.
- Presence of any other clinically significant disease or disorder which, in the opinion of the Investigator (by its nature or by being inadequately controlled), might put the patient at risk due to participation in the study, or may influence the results of the study or the patient's ability to complete the study.
Any clinically significant laboratory abnormality, based on the Investigator's judgment. The following laboratory exclusions apply for all patients:
- AST > 2.5 times the upper limit of normal (ULN)
- ALT > 2.5 times ULN
- Hemoglobin A1c > 6.5%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acthar low dose (40 U)
|
The 40U group will administer 0.5 mL of study medication once a day.
Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week.
The stable Acthar regimen should be maintained for the remainder of the study.
However, dose adjustments may be implemented if needed based on safety.
Other Names:
|
Experimental: Acthar high dose (80 U)
|
The 80U group will administer 1.0 mL of study medication every day.
If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL.
Patients will taper study medication during Week 2 through the remainder of the study.
However, dose adjustments may be implemented if needed based on safety.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Score
Time Frame: Baseline to Week 24
|
Disease activity is based on 24 questions, weighted across nine organ systems, combined into a total score that can range from 0 to 105, but are generally < 20, even with very active disease.
|
Baseline to Week 24
|
British Isles Lupus Assessment Group (BILAG) disease activity index Score
Time Frame: Baseline to Week 24
|
Items are rated as 0 (not present), 1 (improving), 2 (same), 3 (worse), or 4 (new) in the last 4 weeks compared with the previous 4 weeks.
The numerical scores are used to categorize each organ system by an alphabetical score: 'A' reflecting severe disease requiring increases in prednisone to > 20 mg daily and/or addition of immunosuppressive agents, 'B' indicated less active disease, requiring low-dose prednisone and/or symptomatic treatment with NSAIDs and/or antimalarials, 'C' reflecting mild disease requiring only symptomatic therapy, 'D' reflecting previous organ system involvement without current disease activity, and 'E' reflecting no prior or no current disease involvement in that organ system.
|
Baseline to Week 24
|
Physician's Global Assessment Score
Time Frame: Baseline to Week 24
|
The Physician's Global Assessment is a 10 cm visual analogue scale (VAS) anchored at 0 (none) and 3 (severe) with intermediate lines at 1 (mild) and 2 (moderate).
It is designed for the physician to indicate the patient's overall disease activity at a particular visit
|
Baseline to Week 24
|
SELENA Flare Index Score
Time Frame: Baseline to Week 24
|
The SELENA Flare Index categorizes SLE flare as 'mild or moderate' or 'severe' based on six variables
|
Baseline to Week 24
|
SLICC/ACR Damage Index
Time Frame: Baseline to Week 24
|
The SLICC/ACR Damage Index measures irreversible organ damage from either the disease process or treatment, which has been present for ≥ 6 months, in 12 organ systems.
It is an important predictor of long-term mortality and is an independent outcome measure separate from the SLEDAI.
|
Baseline to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medical Outcomes Survey Short Form-36
Time Frame: Baseline to Week 24
|
The SF-36 has been validated in SLE and includes eight domains: physical functioning, role physical, bodily pain, general health perceptions, vitality (which includes fatigue, energy and vigor), social functioning, role emotional and mental-health impact, combined into two summary scores (physical component summary scores [PCS] and mental component summary scores [MCS])
|
Baseline to Week 24
|
FACIT Fatigue Scale
Time Frame: Baseline to Week 24
|
The FACIT-F scale is a 13-item questionnaire to evaluate self-reported fatigue and its impact upon daily activities and function.
The responses are measured on a 4-point Likert scale, with the total score ranging from 0 to 52.
The FACIT-F scale has been validated in SLE patients.
|
Baseline to Week 24
|
Patient's Global Assessment
Time Frame: Baseline to Week 24
|
Subjects rate their global assessment of SLE disease activity on each visit, in response to the question "Considering all the ways your SLE affects you, please mark a vertical line on the scale below for how are you feeling today?" using a 100mm visual analogue scale, where 0 is "very good, no symptoms" and 100 is "very poor, very severe symptoms."
|
Baseline to Week 24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amit Saxena, MD, New York University Medical School
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-00295
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus (SLE)
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedSystemic Lupus Erythematosus (SLE) | Cutaneous Lupus | Juvenile SLEBrazil
-
AstraZenecaNot yet recruitingSystemic Lupus Erythematosus (SLE)
-
Hangzhou Sumgen Biotech Co., Ltd.RecruitingSystemic Lupus Erythematosus (SLE)China
-
Cartesian TherapeuticsRecruitingSystemic Lupus Erythematosus (SLE)United States
-
Oklahoma Medical Research FoundationYale University; Columbia University; NYU Langone Health; Piedmont Heart Institute...RecruitingSystemic Lupus Erythematosus (SLE)United States
-
Phramongkutklao College of Medicine and HospitalCompletedSystemic Lupus Erythematosus, SLEThailand
Clinical Trials on Acthar low dose (40 U)
-
Duke UniversityNational Institutes of Health (NIH)Not yet recruitingObesity | Pediatric Obesity | Asthma in Children | Pediatric AsthmaUnited States
-
EuroPharma, Inc.I.Zhordania Institute of ReproductologyCompleted
-
Albany Medical CollegeUnknownSarcoidosis | Cutaneous SarcoidosisUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Hospital for Special Surgery, New YorkCompletedInterscalene Block | Shoulder ArthroscopyUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
Mansoura Integrated Fertility CenterCompletedPolycystic Ovary SyndromeEgypt
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom